{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-413217","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2026-10-05T12:30:07+00:00","discovered_at":"2026-10-05T12:35:00.296893+00:00","generated_at":"2026-10-12T14:46:18.084054+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome amends BMS license, pays $20M and 4,425,487 shares to end royalties and acquire patents","bullets":["Immunome amended BMS license on Oct. 2, 2026, removing milestone/royalty obligations and assigning varegacestat (AL102) and AL101 patent rights to Immunome.","Immunome paid BMS $20.0 million cash and issued 4,425,487 common shares; after payment, Immunome has no milestone, royalty or other payment obligations to BMS under the License Agreement.","Stock Issuance Agreement requires Immunome to file a resale registration statement by Nov. 16, 2026, effective within 60 days or 5 business days if SEC does not review.","The 4,425,487 shares were issued under Section 4(a)(2) exemption and were not registered under the Securities Act; BMS received resale registration rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-413217","json":"https://secwatch.observer/filing/0001193125-26-413217.json","markdown":"https://secwatch.observer/filing/0001193125-26-413217.md","text":"https://secwatch.observer/filing/0001193125-26-413217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/0001193125-26-413217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526413217/d114908d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:46:18.084054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}